Guest: Stuart Forrest/ CEO at TriggerfishLISTEN TO PODCAST
Guest: Wendy Knowler/ Correspondent at Consumer TalkLISTEN TO PODCAST
Using profit to solve health issues does not work in a pandemic, perhaps at all.
This is a really complex issue. How should we fund the research for more effective drugs to treat conditions that may affect millions, knowing that many will not work and then determine how to price those that do work to cover the costs not just of the drug that did work, but the research for those that did not.
The cost to produce the drug has components that include the search for the potential candidates, the development of the tests on animals and then humans and the ongoing monitoring to determine its effect.
The mechanism to do this has been to have for profit companies get patents for their discoveries and then get a period between 5, 12 and sometimes over 20 years to be able to exclusively supply the drug and set its price.
There is no question that the system can be better. The question is how and despite many attempts by those that have practical alternatives, it does not appear enough has changed to make medicine more accessible.
Could the Covid-19 pandemic provide the public support to overcome the financial resistance that those that benefit from the status quo?
Image credit - Pexels
Guest: Dean Kowarski/ CEO at Real Foods GroupLISTEN TO PODCAST
Guest: Chris Steward/ Portfolio Manager at Ninety OneLISTEN TO PODCAST
Guest: Jonathan Kingsley- Hall/ Fpunder at JKH Business and property ConsultingLISTEN TO PODCAST
Guest: Rob Rose/ Editor at Financial MailLISTEN TO PODCAST
Guest: Alex Thomson/ Co- Founder at Naked InsuranceLISTEN TO PODCAST
Guest: Chris Bishop/ Head of programming at CNBC AfricaLISTEN TO PODCAST